PRESS RELEASE published on 02/28/2025 at 07:30, 1 year 1 month ago Informations privilégiées / Autres communiqués ABIONYX s’engage dans la Déficience LCAT (Maladie de Norum) en soutenant les patients et préparant l'AMM, bénéficiant de la Désignation de Maladie Orpheline en Europe et aux USA ABIONYX EMA Déficience LCAT Maladie De Norum Désignation Orpheline
PRESS RELEASE published on 02/28/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases ABIONYX renews commitment to treat LCAT Deficiency (Norum's disease) and provides updates on advances, including submission of Marketing Authorization Application and Orphan Disease Designation ABIONYX LCAT Deficiency Rare Disease Day Marketing Authorization Application Orphan Disease Designation
BRIEF published on 02/27/2025 at 19:25, 1 year 1 month ago ABIONYX Pharma Reports Stable Revenue and Cash Position for 2024 2024 Financial Results Innovative Therapies ABIONYX Pharma Compassionate Access CRO Industry
BRIEF published on 02/27/2025 at 19:25, 1 year 1 month ago ABIONYX Pharma annonce un chiffre d'affaires et une situation de trésorerie stables pour 2024 Résultats Financiers 2024 ABIONYX Pharma Thérapies Innovantes Accès Compassionnel Industrie Des CRO
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year 1 month ago Inside Information / Information on annual revenues ABIONYX Pharma reports €4.6m revenue and €3.2m cash at the end of Q4 2024. Details on business activities and financial performance included Revenue Cash Position Financial Update Biopharma ABIONYX Pharma
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year 1 month ago Informations privilégiées / Information sur chiffre d’affaires annuel ABIONYX Pharma annonce un chiffre d'affaires consolidé de 4,6M€ et une trésorerie de 3,2M€ au 31 décembre 2024 Chiffre D'affaires Trésorerie Biopharma ABIONYX Pharma Thérapies Innovantes
BRIEF published on 02/20/2025 at 07:35, 1 year 1 month ago ABIONYX Pharma reçoit un soutien de 8,7 millions d'euros pour son projet sur le sepsis France 2030 ABIONYX Pharma Sepsis Soutien Financier Biomédicament
BRIEF published on 02/20/2025 at 07:35, 1 year 1 month ago ABIONYX Pharma receives €8.7 million in support for its sepsis project Financial Support France 2030 ABIONYX Pharma Sepsis Biomedicine
PRESS RELEASE published on 02/20/2025 at 07:30, 1 year 1 month ago Informations privilégiées / Autres communiqués ABIONYX Pharma reçoit 8,7 M€ de soutien de l’Etat pour combattre le sepsis, 3ème cause de décès mondiale, grâce à son biomédicament CER-001 France 2030 ABIONYX Pharma Sepsis Soutien Financier Biomédicament
BRIEF published on 12/11/2024 at 12:16, 1 year 3 months ago Franchissement de seuil par la CDC dans ABIONYX PHARMA Droits De Vote Franchissement De Seuil CDC ABIONYX Pharma Bpifrance Participations
Published on 04/01/2026 at 15:10, 1 hour 20 minutes ago A2Z Announces Audited Full-Year 2025 Financial Results
Published on 04/01/2026 at 15:00, 1 hour 30 minutes ago Karbon-X Named Official Sustainability Partner of the Detroit Red Wings and Detroit Tigers
Published on 04/01/2026 at 14:30, 2 hours ago Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
Published on 04/01/2026 at 14:00, 2 hours 30 minutes ago Dateline Completes A$50M Institutional Placement to Advance Colosseum
Published on 04/01/2026 at 16:24, 6 minutes ago Announcement pursuant to Art. 5 para 1 of Regulation (EU) No. 596/2014 in conjunction with Art. 2 para 1 of the Delegated Regulation (EU) 2016/1052 of the Commission (as amended or replaced from time
Published on 04/01/2026 at 15:17, 1 hour 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 04/01/2026 at 15:16, 1 hour 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 04/01/2026 at 15:14, 1 hour 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/01/2026 at 08:00, 8 hours 30 minutes ago Transfert du contrat de liquidité aupres de Natixis Oddo BHF
Published on 04/01/2026 at 08:00, 8 hours 30 minutes ago Résultats annuels 2025 - ANR par action en hausse de + 8,1 % à 97,10 € - Fonds propres consolidés : 740 M€
Published on 03/31/2026 at 20:08, 20 hours 22 minutes ago SMTPC - Communiqué sur les résultats annuels 2025
Published on 03/31/2026 at 19:05, 21 hours 25 minutes ago SFPI GROUP: implementation of a new liquidity contract
Published on 03/31/2026 at 19:05, 21 hours 25 minutes ago Groupe SFPI : mise en oeuvre d'un nouveau contrat de liquidité
